X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
ADCOCK INGRAM
Jun-14
SUN PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs842342-   
Low Rs572247-   
Sales per share (Unadj.) Rs131.6101.8-  
Earnings per share (Unadj.) Rs32.7-25.6-  
Cash flow per share (Unadj.) Rs38.0-21.3-  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs152.779.9-  
Shares outstanding (eoy) m2,399.26168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.42.9 185.7%   
Avg P/E ratio x21.6-11.5 -188.3%  
P/CF ratio (eoy) x18.6-13.9 -134.4%  
Price / Book Value ratio x4.63.7 125.6%  
Dividend payout %10.70-   
Avg Mkt Cap Rs m1,696,87749,710 3,413.5%   
No. of employees `00017.54.3 408.0%   
Total wages/salary Rs m49,0233,120 1,571.3%   
Avg. sales/employee Rs Th18,028.34,002.0 450.5%   
Avg. wages/employee Rs Th2,798.8726.7 385.1%   
Avg. net profit/employee Rs Th4,479.5-1,008.4 -444.2%   
INCOME DATA
Net Sales Rs m315,78417,181 1,838.0%  
Other income Rs m6,232120 5,179.4%   
Total revenues Rs m322,01617,301 1,861.2%   
Gross profit Rs m100,893-2,977 -3,388.7%  
Depreciation Rs m12,648742 1,705.6%   
Interest Rs m3,998465 859.1%   
Profit before tax Rs m90,479-4,064 -2,226.4%   
Minority Interest Rs m0-11 0.0%   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,116254 4,771.2%   
Profit after tax Rs m78,462-4,329 -1,812.4%  
Gross profit margin %31.9-17.3 -184.4%  
Effective tax rate %13.4-6.2 -214.3%   
Net profit margin %24.8-25.2 -98.6%  
BALANCE SHEET DATA
Current assets Rs m329,53712,584 2,618.8%   
Current liabilities Rs m178,8707,080 2,526.4%   
Net working cap to sales %47.732.0 148.9%  
Current ratio x1.81.8 103.7%  
Inventory Days Days79111 71.2%  
Debtors Days Days83124 67.2%  
Net fixed assets Rs m204,7667,335 2,791.7%   
Share capital Rs m2,39980 3,007.8%   
"Free" reserves Rs m363,9970-   
Net worth Rs m366,39713,485 2,717.1%   
Long term debt Rs m14,3614,739 303.0%   
Total assets Rs m614,10225,474 2,410.7%  
Interest coverage x23.6-7.7 -305.6%   
Debt to equity ratio x00.4 11.2%  
Sales to assets ratio x0.50.7 76.2%   
Return on assets %13.4-15.2 -88.5%  
Return on equity %21.4-32.1 -66.7%  
Return on capital %24.8-19.8 -125.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m19,6340-   
CASH FLOW
From Operations Rs m70,8221,467 4,829.3%  
From Investments Rs m-42,216-450 9,375.3%  
From Financial Activity Rs m-22,8544,301 -531.4%  
Net Cashflow Rs m6,1075,317 114.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.72 Rs / ZAR

Compare SUN PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: PFIZER  J.B.CHEMICALS  MERCK LTD  NATCO PHARMA  STERLING BIOTECH  



Today's Market

Indian Indices Scale Record Highs, India's Current Account Deficit, and Top Stocks in Focus Today(Pre-Open)

Indian share markets continued their momentum during closing hours of trade yesterday and ended the day at their fresh record high levels. Gains were largely seen in the metal sector and energy sector.

Related Views On News

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 21, 2018 09:33 AM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS